-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $187

Benzinga·05/02/2025 13:16:36
Listen to the news
HC Wainwright & Co. analyst Andrew Fein maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $241 to $187.